Anti-Filaggrin Antibody, clone AHF2

Filaggrin (UniProt: P20930; also known as FLG) is encoded by the FLG gene (Gene ID: 2312) in human. Filaggrin, a calcium-binding protein, is synthesized as a large, insoluble, highly phosphorylated precursor with several tandem copies of 324 amino acids in cytoplasmic granules. During terminal differentiation it undergoes dephosphorylation and proteolytic cleavage to remove linker peptides and produce functional basic filaggrin units. It is widely expressed and in skin tissue it is detected mainly in stratum granulosum of the epidermis. During terminal differentiation of mammalian epidermis, it aggregates keratin intermediate filaments and promotes disulfide-bond formation among the intermediate filaments. This creates the intracellular fibrous matrix of the cornified cells. Deimination of arginine to citrulline by peptidylarginine deiminase is reported to result in reduction in its affinity for cytokeratins. The N-terminal region of the mature filaggrin is shown to be heterogenous and is blocked by the formation of pyroglutamate. Clone AHF2 specifically detects profilaggrin and exhibits reactivity in various immunochemical applications. (Ref.: Simon, M., et al. (1996). Biochem. J. 317(pt 1); 173 177; Simon, M., et al. (1995). Clin. Exp. Immunol. 100(1); 90-98; Simon, M., et al. (1995). J. Invest. Dermatol. 105(3); 432-437).

Partially purified Filaggrin from human breast skin tissue.

Quality Control Testing

Evaluated by Immunohistochemistry (Paraffin) in Human skin tissue sections.

Immunohistochemistry (Paraffin) Analysis: A 1:250 dilution of this antibody detected Profilaggrin in Human skin tissue sections.

Tested Applications

Western Blotting Analysis: A representative lot detected Profilaggrin in Western Blotting application. (Sebbag, M., et al. (1995). J Clin Invest.95(6):2672-9; Simon, M., et al. (1995). Clin Exp Immunol. 100(1):90-8; Simon, M., et al. (1995). J Invest Dermatol. 105(3):432-7; Simon, M., et al. (1996). Biochem J. 317(Pt1)(Pt1):173-7).

ELISA Analysis: A representative lot detected Profilaggrin in ELISA application. (Miedouge, M., et al. (2001). Tumour Biol. 22(1):19-26).

Immunohistochemistry Applications: A representative lot detected Profilaggrin in Immunohistochemistry application. (Guy, R., et al. (1998). Dermatology. 196(1):32-7; Chavanas, S., et al. (2006). J Dermatol Sci. 44(2):63-72).

Immunofluorescence Analysis: A representative lot detected Profilaggrin in Immunofluorescence application. (Simon, M., et al. (1995). J Invest Dermatol.;105(3):432-7; Chavanas, S., et al. (2006). J Dermatol Sci.;44(2):63-72).

Electron Microscopy: A representative lot detected Profilaggrin in Electron Microscopy applications (Simon, M., et al. (1995). Clin Exp Immunol. 100(1):90-8; Simon, M., et al. (1995). J Invest Dermatol. 105(3):432-7).

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Clone AHF2 is a mouse monoclonal antibody that detects Profilaggrin.

Purified mouse monoclonal antibody IgG1 in PBS with 0.1% sodium azide with 50% glycerol.

1.0 mg/mL. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Store at -10°C to -25°C. Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.